Workflow
RHHBY to Acquire 89bio for $3.5B, Add Late-Stage MASH Drug to Pipeline
ZACKS·2025-09-19 00:41

Key Takeaways Roche will buy 89bio for 3.5B,withboardsofbothcompaniesapprovingthedealclosinginQ42025.89bio′spegozaferminisinphaseIIItrialsforMASH,includingfibroticandcirrhoticpatients.ETNBshareholderswillget3.5B, with boards of both companies approving the deal closing in Q4 2025.89bio's pegozafermin is in phase III trials for MASH, including fibrotic and cirrhotic patients.ETNB shareholders will get 14.50 per share plus CVRs worth up to 6.00tiedtodrugmilestones.Roche((RHHBY)announcedthatitwillacquireclinical−stagebiopharmaceuticalcompany89bio,Inc.((ETNB)for6.00 tied to drug milestones.Roche ((RHHBY) announced that it will acquire clinical-stage biopharmaceutical company 89bio, Inc. ((ETNB) for 3.5 billion in a bid to augment its portfolio in cardiovascular, renal, and metabolic diseases ...